Krystal Biotech awarded director Catherine Mazzacco 1,658 derivative securities through two transactions dated 2026-09-14, with a stated price of $0 per share. Transaction code A identifies the entries as awards or grants, giving investors a precise record of the insider transaction and its reported pricing.

Key Highlights

  • The transactions used SEC transaction code A.
  • The 1,658 derivative securities were awarded across two separate transactions.
  • The reported transaction price was $0 per share.

Krystal Biotech, Inc. (NASDAQ: KRYS) awarded director Catherine Mazzacco 1,658 derivative securities on 14 September 2026. The filing identifies the securities as derivative securities.

Two Transactions Recorded Under Code A

The award was split across two separate transactions, both using transaction code A. The filing states that both transactions used SEC transaction code A. The reported consideration was $0 per share. Catherine Mazzacco is identified as a director of Krystal Biotech, Inc. and the securities involved are derivative securities.